Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Genus increases profit forecast for FY26 to around £98m and shares rise

Genus forecasts an adjusted pre-tax profit of around £98m for fiscal 2026, beating consensus estimates. The positive revision reflects a stronger-than-expected second half, with robust growth in the pig genetics business (PIC) in Asia and Latin America and double-digit profit growth at the cattle genetics division (ABS) thanks to the Value Acceleration Programme. The company also reports very strong cash conversion, material free cash flow growth and a strengthened balance sheet heading into FY27. The shares rose sharply intraday and closed well above the prior level. » Altro su de.investing.com
Genus posts record profit despite revenue stagnation and announces China joint venture

Genus reports adjusted profit growth of 57% for H1 2026 on flat revenue of £335.6m; adjusted pre-tax profit rose to £55.7m and adjusted earnings per share to 60.8p. Drivers were high-margin licence revenues, strong PIC performance in Asia and a £5.6m milestone payment from a joint venture with Beijing Capital Agribusiness, which expects further payments of around £100m for Q4 FY2026. Regulatory progress for the PRRS‑resistant PRP technology and an increase of the interim dividend to 11.2p underline the strategy, while the shares fell sharply amid doubts about the sustainability of the margins. » Altro su de.investing.com
Genus exceeds expectations and raises 2026 outlook

Genus reported a strong first half of 2026 with an adjusted pre-tax profit of around £50.0m (excluding a milestone payment) or about £55.6m including the milestone. Management now expects a full-year adjusted pre-tax profit to be moderately above the top end of current market expectations (£82.7–85.0m). In December Genus received SASAC approval for the China pig genetics joint venture, triggering a $7.5m (approximately £5.6m) milestone payment; formation and payment are expected in Q3. The full half-year results for the period to 31 December 2025 will be published on 26 February 2026. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2026, GENUS ha già distribuito 0,13€ di dividendi. L'ultimo pagamento è avvenuto a marzo.

Dati finanziari dell'azienda

Nell'ultimo trimestre, GENUS ha registrato ricavi pari a 384,59M€ e un utile netto di 34,15M€

(EUR)	dic 2025	YoY
Ricavi	+384,59M	-
Utile lordo	+359,84M	-
Utile netto	+34,15M	-
EBITDA	+65,78M	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,99Mld€
Numero di azioni	66,41M
Massimo/minimo a 52 settimane	+31,97€ - +26,58€
Rendimento da dividendo	+1,38%
Dividendi TTM	+0,38€
Beta	0,9
Rapporto P/E	+31,92
Rapporto PEG	+0,02
Rapporto P/B	+3,01
Rapporto P/S	+2,27

Profilo aziendale

Genus plc ist als Tiergenetik-Unternehmen in Nordamerika, Lateinamerika, dem Vereinigten Königreich, dem übrigen Europa, dem Nahen Osten, Russland, Afrika und Asien tätig. Das Unternehmen ist in drei Segmenten tätig: Genus PIC, Genus ABS und Genus Forschung und Entwicklung. Unter der Marke PIC verkauft es Sauen, Eber und Sperma für die Zucht von Schweinen mit verschiedenen Eigenschaften für die Schweinefleischproduktion. Unter den Marken ABS, Genus und Bovec vertreibt das Unternehmen außerdem Bullensperma und Embryonen zur Aufzucht von Kälbern mit verschiedenen Merkmalen für die Milch- und Rindfleischproduktion. Darüber hinaus bietet das Unternehmen Landwirten die Geschlechtsbestimmung von Samen, Fortpflanzung und andere technische Dienstleistungen an. Genus plc hat eine strategische Zusammenarbeit mit Beijing Capital Agribusiness Co. Ltd. eine strategische Zusammenarbeit, um die Regulierungs- und Entwicklungsarbeit im Bereich der Resistenz gegen das porcine reproduktive respiratorische Syndrom in China voranzutreiben. Das Unternehmen wurde 1994 gegründet und hat seinen Sitz in Basingstoke, Vereinigtes Königreich.